Literature DB >> 1849504

Cisplatin and etoposide combination therapy for primary glial tumors: preliminary results.

A Boiardi1, A Silvani, I Milanesi, L Munari, C L Solero, M Botturi.   

Abstract

In this preliminary trial we studied 29 patients with primary malignant glial tumors to investigate the effectiveness of cisplatin combined with etoposide on these tumors. Hyperfractionated radiation therapy was given in the course of chemotherapy. The time to tumor progression in these glioblastoma multiforme (GBM) patients encouraged us to continue this treatment in a phase III study.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1849504     DOI： 10.1007/bf02337611

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN： 0392-0461


  18 in total

1.  Synergism between BCNU and irradiation in the treatment of anaplastic gliomas. An in vivo study using the avian sarcoma virus-induced glioma model.

Authors:  P Steinbok; M S Mahaley; R U; D C Zinn; S Lipper; J L Mahaley; D D Bigner
Journal:  J Neurosurg       Date:  1979-11       Impact factor: 5.115

2.  Combination chemotherapy with cisplatin and etoposide for malignant intracranial germ-cell tumors. An experimental and clinical study.

Authors:  T Kobayashi; J Yoshida; J Ishiyama; S Noda; A Kito; Y Kida
Journal:  J Neurosurg       Date:  1989-05       Impact factor: 5.115

3.  Malignant astrocytoma: hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial.

Authors:  D G Payne; W J Simpson; C Keen; M E Platts
Journal:  Cancer       Date:  1982-12-01       Impact factor: 6.860

4.  Etoposide prior to cis-diamminedichloroplatinum in combination chemotherapy: in vitro and in vivo studies.

Authors:  G Zupi; C Greco; A Sacchi; F Calabresi
Journal:  Eur J Cancer Clin Oncol       Date:  1985-12

5.  Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors.

Authors:  D J Stewart; M T Richard; H Hugenholtz; J M Dennery; R Belanger; J Gerin-Lajoie; V Montpetit; D Nundy; J Prior; H S Hopkins
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

6.  In vitro chemosensitivity of brain tumors to cisplatin and its analogues, iproplatin and carboplatin.

Authors:  P Dodion; C Sanders; P Georges; Y Kenis
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  A phase II study of cisplatin therapy in recurrent childhood brain tumors. A report from the Childrens Cancer Study Group.

Authors:  S J Bertolone; E S Baum; W Krivit; G D Hammond
Journal:  J Neurooncol       Date:  1989-05       Impact factor: 4.130

8.  X-ray and cis-diamminedichloroplatinum(II) cross-resistance in human tumor cell lines.

Authors:  J L Schwartz; J Rotmensch; M A Beckett; D R Jaffe; M Toohill; S M Giovanazzi; J McIntosh; R R Weichselbaum
Journal:  Cancer Res       Date:  1988-09-15       Impact factor: 12.701

9.  A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study.

Authors:  D F Nelson; D Schoenfeld; A S Weinstein; J S Nelson; T Wasserman; R L Goodman; S Carabell
Journal:  Int J Radiat Oncol Biol Phys       Date:  1983-08       Impact factor: 7.038

10.  Cisplatin therapy in recurrent childhood brain tumors.

Authors:  A B Khan; B J D'Souza; M D Wharam; L A Champion; L F Sinks; S Y Woo; D C McCullough; B G Leventhal
Journal:  Cancer Treat Rep       Date:  1982-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.